Combined nivolumab and ipilimumab in melanoma metastatic to the brain Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Antineoplastic Combined Chemotherapy Protocols
  • Brain Neoplasms
  • Immunotherapy
  • Ipilimumab
  • Melanoma
  • Skin Neoplasms

abstract

  • Nivolumab combined with ipilimumab had clinically meaningful intracranial efficacy, concordant with extracranial activity, in patients with melanoma who had untreated brain metastases. (Funded by Bristol-Myers Squibb and the National Cancer Institute; CheckMate 204 ClinicalTrials.gov number, NCT02320058 .).

publication date

  • August 23, 2018

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1805453

PubMed ID

  • 30134131

Additional Document Info

start page

  • 722

end page

  • 730

volume

  • 379

number

  • 8